Funding profile · Digital pathology services

HistoWiz

A $32 million Series A announced in October 2021, and a Regulation D record that stops in June 2016. The gap between the two is the whole story of this filing history.

$32.0MSeries A announced Oct 2021, company-reported, no Form D on file
$1.34MTotal sold across the two Form D notices on record
10Investors counted across both Form D filings
10 yrsSince the last HistoWiz securities filing, June 2016

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2012 Incorporated in New York as Histowiz, Inc. Not applicable Not applicable Form D
Feb 2015 Equity offering, exemption code 04 as filed $1,000,000 offered and sold 1 investor; minimum accepted $1,000,000 Form D
Mar 2016 Equity offering, Rule 506(b) $350,000 offered, $344,514 sold 9 investors Form D
Winter 2016 Y Combinator batch Not disclosed Y Combinator YC data
Before Oct 2021 Earlier backers named in the Series A coverage Not disclosed Y Combinator, Zhenfund Company release
Oct 19, 2021 Series A $32,000,000 Vivo Capital (lead), venBio, Asahi Kasei, Jon Oringer Company release, no Form D

What the filings show

Histowiz, Inc. · Form D · filed Jun 7, 2016

First sale
Mar 9, 2016
Offered
$350,000 equity
Sold
$344,514 · $5,486 remaining
Investors
9 · average about $38,279
Exemption
Rule 506(b)
Revenue range
Decline to Disclose
Related persons
Ke Cheng, Brooklyn NY (executive officer, director)
Filing
SEC EDGAR, CIK 0001635476

Histowiz, Inc. · Form D · filed Mar 4, 2015

First sale
Feb 8, 2015
Offered
$1,000,000 equity
Sold
$1,000,000 · nothing remaining
Investors
1 · minimum accepted from an outside investor $1,000,000
Exemption
Code 04 as filed
Use of proceeds
$40,000 to executive officers, directors or promoters
Revenue range
$1 to $1,000,000
Related persons
Ke Cheng, Brooklyn NY (executive officer, director)
Filing
SEC EDGAR, CIK 0001635476

Reading the filings

  1. The entire filed record is $1.34 million.$1,000,000 in 2015 plus $344,514 in 2016 is $1,344,514, taken from ten investors in total, all before the middle of 2016. Every dollar raised since then, including the announced $32 million, sits outside Regulation D.
  2. The 2015 round is one check.One investor, $1,000,000 offered, $1,000,000 sold, and the minimum accepted from an outside investor set at $1,000,000. That shape describes a single backer taking the whole offering, not a syndicate. The same filing reserves $40,000 of the proceeds for payments to executive officers, directors or promoters, and reports company revenue in the $1 to $1,000,000 band.
  3. The 2016 round is the angel round.Nine investors put in $344,514 of a $350,000 offering, about $38,279 each, with the first sale on March 9, 2016, inside the Y Combinator winter batch. The offering closed $5,486 short of its target.
  4. The Series A left no Form D.An offering sold only to accredited investors can rely on Section 4(a)(2) and file nothing, so the absence is not evidence that the money did not arrive. It does mean the first sale date, the investor count and the amount actually sold against the $32 million are known only from the company announcement and the coverage that repeated it.
  5. No filing records the board that governs the Series A.Ke Cheng is the only related person on both notices. Vivo Capital’s Joseph Siletto appears as a board member in the October 2022 CEO announcement, six years after the last filing, and no public filing lists him.
  6. The incorporation year and the founding year disagree.Both Form Ds give 2012 as the year of incorporation in New York. Company releases from 2023 onward say HistoWiz was founded in 2013. Crunchbase records 2012.

Commercial signals

Signal Detail Source type
Intellectual property US 11,900,703, automated tagging of digital histology slides, issued Feb 13, 2024, assigned to HistoWiz, Inc. A second application in the family is published, not granted. Public record
Regulatory No FDA record and no registered trial. GLP compliant histology and immunohistochemistry announced May 30, 2024. No CLIA or CAP accreditation found. Company-stated
Customers Sanofi, Regeneron, Bristol Myers Squibb, Johnson and Johnson, Calico, Revolution Medicines and L’Oréal named in trade reporting, November 2024. Independent
Scale Published customer counts range from more than 500 organizations to over 3,000 global clients, depending on the release. Figures differ
Capacity 10,197 square foot central lab at the Alexandria Center for Life Science, Long Island City, opened March 2023, alongside Brooklyn and Miami sites. Company-stated
Revenue Nearly doubled in the year to October 2022, per a Vivo Capital board member. No figure published since. Company-stated
Change of control No acquisition of HistoWiz was found in SEC filings, acquirer announcements or independent reporting as of September 2026. The company appears independent. Not found

What to watch

  • A Form D, or any announced round, after five years of silence in the securities record.
  • Whether the second application in the tagging patent family issues.
  • Named GLP, toxicology or IND enabling programs, which would put revenue behind the 2024 service expansion.
  • One reconciled customer count, in place of the four now in circulation.
  • Any change of control, which for a venture backed lab of this size would surface first in an acquirer announcement.

The HistoWiz story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • HappiLabs: Also in Healthcare Services. A Chicago service that put PhD scientists to work negotiating lab supply prices for other scientists, built on $20,000 from friends and family in 2012 and acquired by
  • Science Exchange: Also in Healthcare Services. A marketplace for ordering experiments that became procurement software for big pharma, and that sourced the laboratories for the largest public test of whether
  • In Your Corner: Also in Healthcare Services. An online counseling and coaching marketplace that began as Pretty Padded Room in 2011, went through Y Combinator in 2014, and closed in 2016
  • Triomics: Also in Healthcare Services. An oncology-tuned language model that reads the whole cancer chart and hands research coordinators a cited worklist before clinic opens

Sources

  1. Public recordForm D, Histowiz, Inc., CIK 0001635476SEC · Mar 4, 2015
  2. Public recordForm D, Histowiz, Inc., CIK 0001635476SEC · Jun 7, 2016
  3. Public recordUS Patent 11,900,703USPTO · issued Feb 13, 2024
  4. IndependentHistoWiz Raises $32M in Series A FinancingFinSMEs · Oct 20, 2021
  5. IndependentHistoWiz Raises $32-Million Financing to Fully Automate Lab OperationsDrug Development and Delivery · Oct 21, 2021
  6. IndependentOne scientist’s quest to teach machines to see cancer the way doctors doDrug Discovery and Development · Nov 11, 2024
  7. CompanyHistoWiz Raises $32M Series A FinancingPR Newswire · Oct 19, 2021
  8. CompanyHistoWiz Appoints Linh Hoang as CEO and Board MemberBusiness Wire · Oct 25, 2022
  9. CompanyHistoWiz Expands Laboratory Footprint with New Headquarters in QueensBusiness Wire · Mar 20, 2023
  10. CompanyHistoWiz Expands Histology and Pathology Service Offerings to Include GLPBusiness Wire · May 30, 2024
  11. PartnerProtege and HistoWiz Partner to Digitize and Unlock Pathology Data for AI TrainingProtege · Mar 19, 2025

Compiled from SEC, USPTO and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in HistoWiz. This page is not an offer to sell or a recommendation to buy any security.